Back to search

Article

Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T cell therapies

2025-09-26

Abstract excerpt

<h4>ABSTRACT</h4> Patients with T-cell lymphomas and leukemias have overall poor outcomes due to the lack of targeted and effective treatments, particularly in the relapsed and refractory settings. Development of chimeric antigen receptor (CAR) T-cells against T-cell neoplasms is limited by a lack of discriminating T-cell antigens that allow for effective anti-tumor responses while preventing CAR T-cell fratricid...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
926977e5-f4ba-58e1-9981-2fa70b12dd20
DOI
10.1101/2025.09.24.677515
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T cell therapiesDOI 10.1101/2025.09.24.677515
Select a neighboring publication to make it the new centre.